Michael Calwas Comment On Regulatory Notice 22-08
Over the years, I have used many of the "complex products" that are the subject of Regulatory Notice 22-08 including leveraged ETPs, inverse ETPs and options. In all cases, I did the appropriate research on these products to understand how they work and the risks associated with using them. These products have been an important part of my investment portfolio to either hedge certain positions or to leverage other positions. In all cases, if I reviewed a complex product and it was unclear to me what it was or how it worked, I simply did not include it in my investment portfolio.